Back to top

immuno-therapy: Archive

Zacks Equity Research

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.

CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change IBRXNegative Net Change

Zacks Equity Research

Lilly (LLY) Hits Record High on Crohn's Disease Study Data

Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.

JNJNegative Net Change LLYPositive Net Change ABBVPositive Net Change